Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

American Journal of Transplantation

Volumn 5, Issue 12, 2005, Pages 2894-2900

  Funch, Donnie P ^a   Walker, Alexander M ^a   Schneider, Gary ^a   Ziyadeh, Najat J ^a   Pescovitz, Mark D ^b  

^a Ingenix Inc   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Acyclovir; Ganciclovir; Post transplant lymphoproliferative disease; Renal transplantation

Indexed keywords

ACICLOVIR; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGE; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG POTENCY; DRUG USE; EPSTEIN BARR VIRUS; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; SEROLOGY; POSTOPERATIVE COMPLICATION; RISK FACTOR;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 31744433895     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01115.x     Document Type: Article

References (31)

1. Hanto DW Frizzera G Purtilo DT et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981 41 : 4253 4261.
2. Harris NL Ferry JA Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematology Workshop. Semin Diagn Pathol 1997 14 : 8 14.
3. Nalesnik MA. Clinicopathologic features of posttransplant lymphoproliferative disorders. Ann Transplant 1997 2 : 33 40.
4. Aris RM Maia DM Neuringer IP et al. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med 1996 154 : 1712 1717.
5. Walker RC Paya CV Marshall WF et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995 14 : 214 221.
6. Hanto DW Frizzera G Gajl-Pecsalska KJ Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985 39 : 461 472.
7. Cockfield SM Preiksaitis JK Jewell LD Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factors in analysis in a single centre. Transplantation 1993 56 : 88 96.
8. Ho M Miller G Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in postransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985 152 : 876 886.
9. Birkeland SA Anderson HK Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999 67 : 1209 1214.
10. Green M Reyes J Webber S Rowe D. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001 3 : 97 103.
11. McDiarmid SV Jordan S Kim GS et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998 66 : 1604 1611.
12. Darenkov IA Marcarelli MA Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997 64 : 848 852.
13. Malouf MA Chhajed PN Hopkins P Plit M Turner J Glanville AR. Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 2002 21 : 547 554.
14. Kuo PC Dafoe DC Alfrey EJ Sibley RK Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995 59 : 135 138.
15. Biron KK Stanat SC Sorrell JB et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl} guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985 82 : 2473 2477.
16. Kremers HM Funch DP Robson RA et al. A combination study design to examine mycophenolate mofetil (MMF) and PTLD in renal transplant patients. Pharmacoepidemiol Drug Saf 1999 8 : 509 518.
17. Manez R Breinig MC Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997 176 : 1462 1467.
18. Muti G Cantoni S Oreste P et al. Cooperative Study Group on PTLDs. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002 87 : 67 77.
19. Shahinian VB Muirhead N Jevnikar AM et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation 2003 75 : 851 856.
20. Opelz G Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004 4 : 222 230.
21. Keever-Taylor CA Behn B Konings S Orentas R Davies B Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy 2003 5 : 323 335.
22. Hopwood PA Brooks L Parratt R et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002 74 : 194 202.
23. Qu L Green M Webber S Reyes J Ellis D Rowe D. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000 182 : 1013 1021.
24. Babel N Schwarzmann F Pruss A Volk HD Reinke P. Monoclonal gammopathy of undetermined significance (MGUS) is associated with an increased frequency of Epstein-Barr Virus (EBV) latently infected B lymphocytes in long-term renal transplant patients. Transplant Proc 2004 36 : 2679 2682.
25. Razonable RR Paya CV. Herpresvirus infections in transplant recipients: current challenges in the cliical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003 10 : 60 65.
26. Gottschalk S Rooney CM Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005 56 : 29 44.
27. Khatri V Baiocchi RA Peng R et al. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 1999 163 : 500 506.
28. Lowance D Neumayer HH Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999 340 : 1462 1470.
29. Gane E Saliba F Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997 350 : 1729 1733.
30. Winston DJ Busuttil RW. Randomised controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004 77 : 305 308.
31. Cherikh WS Kauffman HM McBride MA Maghirang J Swinnen LJ Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003 76 : 1289 1293.